Skip to main content

and
  1. Article

    Open Access

    Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

    Chimeric Antigen Receptor (CAR) T cells are now standard of care (SOC) for some patients with B cell and plasma cell malignancies and could disrupt the therapeutic landscape of solid tumors. However, access to...

    Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G. Mancini in Molecular Cancer (2023)

  2. Article

    Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

    Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease progression, and neurotoxicity remains a challenge. Biom...

    Zinaida Good, Jay Y. Spiegel, Bita Sahaf, Meena B. Malipatlolla in Nature Medicine (2022)

  3. Article

    Open Access

    GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

    Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system1. We have previously shown that the disialog...

    Robbie G. Majzner, Sneha Ramakrishna, Kristen W. Yeom, Shabnum Patel in Nature (2022)

  4. Article

    Open Access

    CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

    Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL)...

    Jay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed M. Hossain, Jean Oak in Nature Medicine (2021)

  5. No Access

    Article

    HLA-haplotype loss after TCRαβ/CD19-depleted haploidentical HSCT

    David C. Shyr, Bing M. Zhang, Gopin Saini, Nahid D. Madani in Bone Marrow Transplantation (2021)